ArticleBMC cancer2015
Serum irisin levels are lower in patients with breast cancer: association with disease diagnosis and tumor characteristics.
Article in BMC cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 2 syntheses or guidelines pooled it, 115 citations in OpenAlex.
- Correlations between circulating adipokines and hepatocellular carcinoma: a Systematic Review and meta-analysis.Frontiers in endocrinology · 2025Pooled it
- Implication of Irisin in Different Types of Cancer: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2022Pooled it
- Effects of exercise or metformin on myokine concentrations in patients with breast and colorectal cancer: A phase II multi-centre factorial randomized trial.Journal of cachexia, sarcopenia and muscle · 2024Trial
- The impact of high-intensity interval exercise training on NK-cell function and circulating myokines for breast cancer prevention among women at high risk for breast cancer.Breast cancer research and treatment · 2021Trial
- Muscle-Tumor Crosstalk in Exercise Oncology: Exercise-Induced Myokines and Cancer Cachexia.Cancers · 2026Review
- Prognostic impact of MRI-based cervical skeletal muscle mass on survival in parotid gland carcinoma.Japanese journal of clinical oncology · 2026Article
- The relationship between sarcopenia and breast cancer: mechanistic pathways and clinical relevance.Frontiers in cell and developmental biology · 2026Review
- Myokines in cancer: bridging molecular mechanisms to biomarker discovery and therapeutic innovation.Frontiers in oncology · 2026Review
- Diagnostic and Therapeutic Value of the Exercise-Induced Myokine Irisin in Cancer Biology: A Comprehensive Review.Diseases (Basel, Switzerland) · 2025Review
- Irisin Concentrations in Children and Adolescent Cancer Survivors and Their Relation to Metabolic, Bone, and Reproductive Profile: A Pilot Case-Control Study.Journal of clinical medicine · 2025Article
- Irisin's Dual Role in Malignant Tumors and Its Potential as a Biomarker and Therapeutic Target.Drug design, development and therapy · 2025Review
- Irisin promotes hair growth and hair cycle transition by activating the GSK-3β/β-catenin pathway.Experimental dermatology · 2024Article
- Exercise affects high-fat diet-stimulated breast cancer metastasis through irisin secretion by altering cancer stem cell properties.Biochemistry and biophysics reports · 2024Article
- Irisin prevents trabecular bone damage and tumor invasion in a mouse model of multiple myeloma.JBMR plus · 2024Article
- Outcomes of physical exercises on initiation, progression, and treatment of breast cancer.Cell communication and signaling : CCS · 2024Review
- Evaluate the Serum of Irisin, Omentin-1, and Oxidative Status in Males with Prostatic Cancer.Reports of biochemistry & molecular biology · 2024Article
- Article
- Recent progress in understanding mitokines as diagnostic and therapeutic targets in hepatocellular carcinoma.World journal of clinical cases · 2023Review
- Review
- The Role of Irisin/FNDC5 Expression and Its Serum Level in Breast Cancer.International journal of molecular sciences · 2023Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIrisin is a recently discovered myokine, involved in the browning of white adipose tissue. To date, its function has been mainly associated with energy homeostasis and metabolism, and it has been proposed as a promising therapeutic target for obesity and metabolic diseases. This is the first study investigating the role of irisin in human breast cancer.
methodsParticipants included one hundred and one (101) female patients with invasive ductal breast cancer and fifty one (51) healthy women. Serum levels of irisin, leptin, adiponectin and resistin were quantified in duplicates by ELISA. Serum levels of CEA, CA 15-3 and Her-2/neu were measured on an immunology analyzer. The association between irisin and breast cancer was examined by logistic regression analysis. The feasibility of serum irisin in discriminating breast cancer patients was assessed by ROC curve analysis. Potential correlations with demographic, anthropometric and clinical parameters, with markers of adiposity and with breast tumor characteristics were also investigated.
resultsSerum levels of irisin were significantly lower in breast cancer patients compared to controls (2.47 ± 0.57 and 3.24 ± 0.66 μg/ml, respectively, p < 0.001). A significant independent association between irisin and breast cancer was observed by univariate and multivariate analysis (p < 0.001). It was estimated that a 1 unit increase in irisin levels leads to a reduction in the probability of breast cancer by almost 90%. Irisin could effectively discriminate breast cancer patients at a cut-off point of 3.21 μg/ml, with 62.7% sensitivity and 91.1% specificity. A positive association with tumor stage and marginal associations with tumor size and lymph node metastasis were observed (p < 0.05, p < 0.01, p < 0.01, respectively).
conclusionsOur novel findings implicate irisin in breast cancer and suggest its potential application as a new diagnostic indicator of the presence of disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.